Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avexa Of Australia Reports Good Results With HIV Drug

This article was originally published in PharmAsia News

Executive Summary

Australian drug maker Avexa reports positive results from a Phase II study of its apricitabine HIV drug to treat patients unresponsive to GlaxoSmithKline's Epivir (lamivudine). Avexa CEO Julian Chick said the study showed the firm's drug to be at least as good as the safest HIV drug on the market. The study reported the drug reduced the AIDS-causing virus to insignificant levels in 89 percent of patients. Avexa seeks to license marketing rights to a larger partner so it can complete the studies this year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts